Avacta Group PLC (LON:AVCT)

Avacta Group PLC (LON:AVCT)

Share Price
26.75 p
0 (0.00 %)
Market Cap
£31.07 m
Proactive Investors - Run By Investors For Investors

Avacta Group PLC

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

Market: AIM:AVCT
52-week High/Low: 51.000p / 21.000p
Sector: Pharma & Biotech
Market Cap: £31.07 m
Website: www.avacta.com
col 3
col 4
col 5
col 6

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT) pitches the company to investors. For more information visit www.avacta.com

Big Picture – A Deep Dive Examination of Avacta Group PLC

Avacta Group PLC Snapshot

Our mission is to shape the future of medicine by providing powerful reagents for research and diagnostics, and by developing safe and efficacious medicines.

"What really excites me, and drives the company, is the opportunity to change the way life scientists explore the complexity of the proteome and the myriad of interactions that define us as humans."


What is an Affimer?

Affimer reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations. They can be used to detect difficult targets, can easily be formatted for a wide range of applications and can be easily and cost effectively manufactured.

Please click here for more info.

Reagents & Diagnostics

Affimer reagents are ideal tools for use in a wide variety of diagnostic and research applications. With a rapid development timeline Affimer reagents represent a quick solution to rapidly unfolding research needs and ever growing needs for quality diagnostic reagents with consistent supplies. Custom Affimer solutions are available to meet your Diagnostic and Research needs.

Affimer technology offers highly specific target recognition in a variety of complex samples, while retaining both chemical and thermal stability. Affimer molecules offer flexibility in formatting via both genetic and chemical means. A single strategic cysteine residue addition allows for site specific functionalisation with enzymes, dyes, fluors, or immobilization onto a variety of surfaces. In addition to classical chemical methods of modification, we are also able to express genetic modifications to optimise performance (GFP, carrier proteins, and even multimers).

We develop highly specific, reproducible, and stable tools for use in point of care (POC) tests, ligand binding assays and bioprocessing and separations from complex matrices.


Developing the next generation of biotherapeutics

Avacta is engaged in the development of innovative cancer immunotherapies using its proprietary Affimer® technology. Affimers are a novel class of small (14kDa) therapeutic proteins based on the naturally occurring human protease inhibitor Stefin A.

Avacta’s mission is to extend the patient benefits of cancer immunotherapies by taking advantage of the differentiating features of the Affimer scaffold such as its small size, flexible formatting, stability and ease of conjugation. We are building an in-house pipeline of bi-specific therapeutics as well as novel tumour microenvironment activated drug conjugates (TMACTM) combining Affimer immune-checkpoint modulators with pro-inflammatory drugs.

Avacta has also established several strategic alliances making the Affimer technology available to partners through licensing and collaborative development projects in oncology and inflammatory diseases.


Avacta Group Board of Directors

Senior Management


Wetherby site

Unit 20, Ash Way
Thorp Arch Estate, Wetherby
LS23 7FA

Take a virtual tour of our Wetherby site

Cambridge site

Unit B, 1 Lion Works, Station Road East
Whittlesford, Cambridge
CB22 4WL

Take a virtual tour of our Cambridge site

Investor relations

Yellow Jersey PR
Top Floor, 70-71 Wells Street



Columns Including AVCT


Market Reports Including AVCT

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use